examining new oncology distribution channels and the ......examining new oncology distribution...
TRANSCRIPT
Examining New Oncology Distribution Channels and the Integrated Role of Specialty PharmacyMatt Farber
Senior Director, Oncology Disease State Management
Walgreens
Role of the Specialty Pharmacy
Specialty pharmacy is a model that deals primarily with medications and pharmaceuticals that:
• Treat complex and rare diseases
• May require special handling
• Require ongoing patient care and monitoring of side effects
• Are high in cost
• Subject to limited or restricted distribution
• Require complex payer support
• Are approved with a Risk Mitigation Strategy (REMS)
2
Role of the Specialty Pharmacy
Increased emphasis on:
• Patient-centric care
• Medication education and clinical support
• Collaboration with other healthcare team members
• Ability to use metrics to drive optimization of patient care
• Ability to assist patient in accessing supportive resources
3
Medications used to treat:
• Complex conditions
• Rare conditions
Primary Administration
• Injected
• Oral
• Infuseds
Specialty Products
Such as:
▪ Hepatitis C
▪ Fertility
▪ HIV
▪ Multiple sclerosis
▪ Oral oncology
▪ Psoriasis/Psoriatic Arthritis
▪ Respiratory syncytial virus
▪ Crohn’s Disease
▪ Rheumatoid Arthritis
▪ Transplant
▪ Rare/Orphan Conditions
4
Specialty pharmacy history
1990s 2000 Today Tomorrow
Betaseron, Crixavanand Synagis launched
Impact ofthe Hub,oral oncology explodes
Orphan drugs take the stage
Biosimilarsandgenerics
5
Role of Specialty Pharmacy
Specialty Pharmacy lives at the intersection of the key players in oncology care
6
Specialty Pharmacy
Patients
Physicians Payers
Pharma
Why turn to SP?
• Data is king!!
• REMS coordination/ management
• Inventory management
• Benefit management
• Cost control
7
What industry needs to consider
Pharma
• SPs need to be able to engage patients effectively
• Collect clinical and patient feedback to meet quality reporting requirements of new payment models
• Help patients and providers understand the implications of specific medications
Payers
• Decrease inappropriate utilization
• Ensure dosing accuracies
• Reduce acquisition cost
• Coordinate reimbursement and eligibility 8
Adherence
• Given the high cost of therapies, adherence is vital
• Better clinical outcomes
• Cuts down on waste
• Patients falling off therapies cost the system more money
• All SPs will have programs to address this
• Walgreens Connected Care program
• Set program that is in contact with patients throughout their treatment, from before the script is filled to preset check-ins (Day 10, 20), and prior to refills
• Call schedule can be customized
• Ultimately, we are collecting data on adherence and reasons for non adherence
• From clinical to financial to other reasons9
Adherence
• As an example, in oncology, here are a few of the data points being collected with each patient:
• Number of missed doses and reasons
• Side Effects
• Customizable
• Refills
10
Purpose of Walgreens Connected Care℠Oncology Program
Identify patients at risk for non-adherence
• Less than 80% of doses taken• Experiencing side effects
• Dosing instructions
• Tips for remembering doses• Side effect management
• Care Notes related to patient-reported issues
11©2014 Walgreen Co. All rights reserved. Confidential and proprietary information.
Identify patients at risk for non-adherence
Offer support/care through clinician counseling
Keep provider informed
1
2
3
Walgreens Connected Care℠ Oncology Program
Connected Care
Oncology
• All patients for all self-administered anti-cancer medications
• Foundational clinical program
Cycle Management
Program
• Subset of Connected Care Oncology
• Increased level of support
• Medication specific
Split Fill
(Monitored Dispense)
• Subset of CMP - by payer
12©2014 Walgreen Co. All rights reserved. Confidential and proprietary information.
Cycle Management Program
Key components of the program include:
• Initial assessment by clinician
Patient and caregiver education
• Mid-cycle and End-of-cycle assessments by clinician
Documentation of side effects (targeted by medication)
Side effect grading for selected side effects
Adherence assessment
Counseling on side effects/adherence barriers
Oncology Report Card faxed to physician
• Monthly follow-up calls
Escalation to a clinician as needed
©2014 Walgreen Co. All rights reserved. Confidential and proprietary information.
13
Self-administered products
©2014 Walgreen Co. All rights reserved. Confidential and proprietary information.
14
CMP Medications Non-CMP Medications
Afinitor**
Bosulif
Erivedge
Gleevec
Inlyta
Jakafi
Mekinist
Nexavar**
Sprycel**
Stivarga
Sutent**
Tafinlar
Tarceva**
Targretin**
Tasigna**
Thalomid
Tykerb
Votrient**
Xalkori
Xtandi
Zelboraf
Zolinza**
Zytiga
Hycamtin
Intron A
Matulane
Pomalyst
Revlimid
Sylatron
Temodar*
Xeloda*
*generics also included**split fill eligible
What does the future hold?
• Specialty pharmaceutical spending is on the rise and is expected to increase from approximately $55 billion in 2005 to $1.7 trillion in 20302 , according to the Pharmaceutical Care Management Association. That reflects an increase from 24% of total drug spend in 2005 to an estimated 44% of a health plan’s total drug expenditure in 2030
• Currently, three pharmacies -- Express Scripts, CVS Caremark and Walgreens -- make up more than 50% of the specialty drug market while the rest of the market is comprised of hundreds of smaller specialty pharmacies, including Diplomat pharmacy and Omnicare’s advanced care scripts
15http://www.imshealth.com/deployedfiles/imshealth/Global/North%20America/United%20States/Managed%20Markets/5-29-14%20Specialty_Drug_Trend_Whitepaper_Hi-Res.pdf
